NantKwest (NK) Announces Presentation of Analysis for Ongoing Phase II Merkel Cell Carcinoma Study at SITC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/16/2024
- Dow futures up on UnitedHealth boost; bond yields, Mideast tensions weigh
- UnitedHealth to take up to $1.6 billion hit from Change Healthcare hack this year
- Morgan Stanley's profit beats as investment banking rebounds
- Johnson & Johnson (JNJ) posts mixed results, narrows full-year guidance
- Stocks sag, dollar up as 'higher for longer' rate view takes root
- Trump Media & Technology Group (DJT) Files S-1
- Tesla (TSLA) Senior VP Drew Baglino Is Said To Leave The Company - Bloomberg
- General Motors (GM) Said to be Moving Detroit HQ to Dan Gilbert's Hudson Tower - Bloomberg
- The Israeli Air Force Has Completed Its Preparation For An Imminent Attack Against Iran - Reuters
- Biohaven Pharma (BHVN) presents update on degrader platform and summary of progress to date in Phase 1 single ascending dose study for BHV-1300
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
- After-hours movers: Tesla, Gildan Activewear, Macatawa Bank, and more
- Midday movers: Goldman Sachs and Meta Platforms rise; Apple and Tesla fall
- Nike, Alpine Immune Sciences rise premarket; CarMax, Robinhood and Regeneron fall
- After-hours movers: Alpine Immune Sciences, Costco, and more
NantKwest Announces Achievement of End Point in Merkel Cell Carcinoma Phase II Trial With Evidence of Efficacy of Activated Natural Killer (aNK) Cells in Solid Tumors
November 14, 2016 4:08 PM ESTPromising Clinically Meaningful Responses Seen Including a Radiological Complete Response in Early Data Analysis Presented at the 31st Annual Meeting of the Society for Immunotherapy of Cancer
CULVER CITY, Calif.--(BUSINESS WIRE)-- NantKwest Inc. (Nasdaq: NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of the immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases, announced a presentation of early analysis of the Companys ongoing Phase II Merkel cell carcinoma study at the 31st Annual Meeting of the Society for... More
